IV drug succeeds in 50% of patients with unresectable SCC

Cemiplimab may be an option for people with high-risk squamous cell carcinoma that has persisted after surgery and radiotherapy, says Chrysalyne Schmults, a vice chair of surgical oncology at Brigham and Women's Hospital. The intravenous monoclonal antibody drug has about a 50% efficacy rate in patients with unresectable SCC, but the treatment is not appropriate for patients who have had an organ transplant or who have an immune-mediated disease, Schmults says.

Dermatology Times online (1/20)